In traditional phase I and II clinical trial designs, toxicity and efficacy are often modelled as binary outcomes. Such methods ignore information on when the outcome event occurs, such as experiencing toxicity or achieving cure or remission. They also have difficulty accommodating a high...

We propose new model-based methods for unit non-response in two-stage survey samples. A commonly used design-based adjustment weights respondents by the inverse of the estimated response rate in each cluster (method WT). This approach is consistent if the response probabilities are constant...

Treating patients with a combination of agents is becoming commonplace in cancer clinical trials, with biochemical synergism often the primary focus. In a typical drug combination trial, the toxicity profile of each individual drug has already been thoroughly studied in single-agent trials,...